5.12
Precedente Chiudi:
$5.09
Aprire:
$5.1
Volume 24 ore:
747.24K
Relative Volume:
0.90
Capitalizzazione di mercato:
$230.93M
Reddito:
-
Utile/perdita netta:
$-32.74M
Rapporto P/E:
-6.2439
EPS:
-0.82
Flusso di cassa netto:
$-24.89M
1 W Prestazione:
+48.41%
1M Prestazione:
+49.27%
6M Prestazione:
-60.31%
1 anno Prestazione:
-56.57%
Third Harmonic Bio Inc Stock (THRD) Company Profile
Nome
Third Harmonic Bio Inc
Settore
Industria
Telefono
(209) 727-2457
Indirizzo
1700 MONTGOMERY STREET, SAN FRANCISCO
Confronta THRD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
THRD
Third Harmonic Bio Inc
|
5.12 | 230.93M | 0 | -32.74M | -24.89M | -0.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.49 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.91 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
605.38 | 36.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
230.93 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.84 | 25.73B | 3.81B | -644.79M | -669.77M | -6.24 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-28 | Downgrade | Stifel | Buy → Hold |
2025-02-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2025-02-11 | Downgrade | Raymond James | Outperform → Mkt Perform |
2024-08-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-06-18 | Iniziato | Stifel | Buy |
2024-06-07 | Iniziato | Raymond James | Outperform |
2022-12-16 | Downgrade | Jefferies | Buy → Hold |
2022-12-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-10-10 | Iniziato | Cowen | Outperform |
2022-10-10 | Iniziato | Jefferies | Buy |
2022-10-10 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Third Harmonic Bio Inc Borsa (THRD) Ultime notizie
Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties - TipRanks
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered - MSN
$26bn Brighton Jones hires new CFO - Citywire
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Third Harmonic outlines plans for dissolution - BioPharma Dive
Third Harmonic Bio sees initial distribution of $5.13-$5.33 from liquidation - TipRanks
Third Harmonic Bio plans to liquidate the company, sell urticaria treatment - Seeking Alpha
Third Harmonic Bio Stock Is Up 40% Monday: What's Happening? - Benzinga
Third Harmonic Bio plans liquidation and asset sale By Investing.com - Investing.com Canada
Third Harmonic Announces Liquidation And Cash Return, Stock Jumps - Nasdaq
Third Harmonic to shutter; Future Pak once again targets Theratechnologies - Endpoints News
Third Harmonic Bio Plans Liquidation With Lucrative Payouts - Finimize
Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Third Harmonic Bio announces plan of liquidation and dissolution - TipRanks
Third Harmonic Bio Announces Plan Of Liquidation And Dissolution - MarketScreener
Third Harmonic Bio Announces Plan of Liquidation and Dissolution - The Manila Times
Third Harmonic Bio plans liquidation and asset sale - Investing.com
Third Harmonic Bio to Return $255M to Shareholders in Major Cash Distribution - Stock Titan
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Fierce Biotech Layoff Tracker 2025: Opthea reduces workforce by 65%; Organon lays off 93 staffers - Fierce Biotech
Third Harmonic stock rating cut by Raymond James - MSN
Third Harmonic Bio initiates process to identify opportunities to maximize value - TipRanks
Hold Rating for Third Harmonic Bio, Inc. Amid Strategic Exploration and Cautious Development Approach - TipRanks
Stifel Downgrades Third Harmonic Bio (THRD) - MSN
Stifel Nicolaus Downgrades Third Harmonic Bio to Neutral From Buy, Adjusts Price Target to $5 From $23 - MarketScreener
Third Harmonic Bio Reports 2024 Financial Results and Strategic Plans - TipRanks
Third Harmonic Bio reports FY24 EPS ($1.09) vs. (78c) last year - TipRanks
Stifel cuts Third Harmonic stock rating to hold, slashes target to $5 - Investing.com
Third Harmonic Bio Q4 Net Income USD -13.1 Million - Marketscreener.com
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Lower Operating Costs, Offsetting 11% Revenue Decrease Due to Business Transition; Hosts Investor Call Today at 10am ET - The Manila Times
Third Harmonic Bio, Inc. Announces Rise In Full Year Profit - Nasdaq
Third Harmonic's $285M War Chest Powers Phase 2 CSU Drug Development Amid Strategic Shift - Stock Titan
Third Harmonic Bio Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
2025 R&D layoffs tracker: 53,686 and counting - R&D World
Flagship startup raises $200M in pursuit of ‘scientific superintelligence’ - BioPharma Dive
Third Harmonic Bio Advances THB335 for Inflammatory Diseases - TipRanks
THB-335 counteracts cutaneous anaphylaxis in vivo - BioWorld Online
Third Harmonic Bio Inc Azioni (THRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):